FDA Approves Liquid Biopsy To Identify Patients With Metastatic Lung Cancer Who Carry Specific EGFR Mutations
August 10, 2020
MedPage Today (8/7, Ingram) reports that “the FDA on Friday approved the Guardant360 CDx assay to identify” patients with “metastatic lung cancer...who carry specific EGFR mutations, making them eligible for upfront treatment with osimertinib (Tagrisso).”...